Tevogen (TVGN) EBITDA (2023 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly EBITDA came in at -$5.4 million in Q1 2026, up 47.85% YoY from -$3.7 million in Q1 2025, and down 17.15% on a QoQ basis from -$4.6 million in Q4 2025.
Tevogen (TVGN) EBITDA (2023 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 4 years of EBITDA data on file, last reported at -$5.4 million in Q1 2026.
- Quarterly EBITDA rose 47.85% year-over-year to -$5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.2 million (up 38.42% YoY) and the FY2025 annual result came in at -$26.1 million, up 51.2% from the prior year.
- EBITDA eased to -$5.4 million in Q1 2026, from -$4.6 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$2.0 million in Q4 2023 to a low of -$29.5 million in Q1 2024.
- A 4-year average of -$7.2 million and a median of -$5.4 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA sank 1169.93% — and 2025, when it surged 64.91%.
- Tracing TVGN's EBITDA over 4 years: stood at -$2.0 million in 2023, then sank by 366.0% to -$9.4 million in 2024, then surged by 50.76% to -$4.6 million in 2025, then slipped by 17.15% to -$5.4 million in 2026.
- The last three EBITDA figures came in at -$5.4 million (Q1 2026), -$4.6 million (Q4 2025), and -$5.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 133.12 Mn |
| 10 | Tevogen | 25.98 Mn | 25.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.40 Mn |
| Dec 31, 2025 | -4.61 Mn |
| Sep 30, 2025 | -5.73 Mn |
| Jun 30, 2025 | -5.44 Mn |
| Mar 31, 2025 | -10.36 Mn |
| Dec 31, 2024 | -9.36 Mn |
| Sep 30, 2024 | -6.09 Mn |
| Jun 30, 2024 | -8.60 Mn |
| Mar 31, 2024 | -29.52 Mn |
| Dec 31, 2023 | -2.01 Mn |
| Sep 30, 2023 | -2.33 Mn |
| Jun 30, 2023 | -2.18 Mn |
| Mar 31, 2023 | -2.32 Mn |